Overview

Ubiquinon (Coenzyme Q10) Application After Gingival Recession Coverage

Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
0
Participant gender:
All
Summary
This randomised double blinded clinical trial has the aim to assess the effect of Ubiquinon (Coenzyme Q10) on early wound healing following gingival recession coverage. Coenzyme Q10 (CoQ10) is a critical intermediate of the mitochondrial electron transport chain for the synthesis of adenosine triphosphate. The biological importance of CoQ10 is related to antioxidant activity, which can scavenge free radicals as well as restore the antioxidant defence system. Both in vitro and animal studies have suggested that CoQ10 acts as anti-inflammatory agent reducing the inflammatory response by inhibiting the translocation of nuclear factor kappa beta into the nucleus. Gingival recessions particularly in the esthetic area have become a common indication for treatment. The use of subepithelial palatal connective tissue graft (SCTG) in conjunction with either a coronally advanced flap (CAF) or a coronally advanced tunnel are well established techniques for both the treatment of single and multiple gingival recessions. Interestingly, despite the fact that CoQ10 is widely investigated, virtually no information exists on its effects upon early wound healing of oral tissues. Therefore, the aim of this study is to investigate the effect of CoQ10 on wound healing after gingival recession surgery.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University of Bern
Treatments:
Coenzyme Q10
Criteria
Inclusion Criteria:

- Patients with single and multiple Miller class I, II and III gingival recessions will
be included

- Written informed consent

Exclusion Criteria:

- Patients with a history of chronic inflammatory disease

- Patients with severe systemic diseases

- Patients with any sign of clinical infection

- Patients smoking > 5 cigarettes

- Pregnant or lactating women

- Patients < 18 years of age